We are reviewing plans for dementia in England and further information will be available in due course. NHS England continuously reviews potentially promising new medicines which might provide benefits to patients in future, including Lecanemab.

We have had no specific discussions. NHS England continuously reviews potentially promising new medicines which might provide benefits to patients in future, including Lecanemab.

The Home Office has regular engagement with the UK Health Security Agency (UKHSA) on matters of communicable and notifiable diseases detected at Western Jetfoil and Manston.

Directors of Public Health do attend operational asylum accommodation meetings relating specifically to health, either in person or through representatives. These are multi-agency forums, where any issues or concerns around the management of infectious diseases in asylum accommodation can be discussed. However, the collaborative approach to managing communicable diseases within the context of Manston and Western Jetfoil and reducing the risk of their spreading is led by UKHSA and supported by the Home Office.

The Home Office and DLUHC 2nd Permanent Secretary wrote to Directors of Public Health, outlining the Home Office's ongoing programme of work to limit the spread of infectious diseases in hotels.

The Home Office works closely with UKHSA and the NHS in tracking those with communicable diseases.

Any cases of Communicable diseases are dealt with in conjunction with UKHSA local Health Protection Team and this includes creating a pathway for the safe dispersals of persons with communicable diseases from site into appropriate accommodation ensuring all relevant parties are informed prior to the dispersal. Any decisions are taken in liaison with UKHSA and local NHS partners.

All suspected cases of communicable disease are isolated in line with public health guidance. Every confirmed case is referred to the UK Health Security Agency by the laboratory.

The 1995 agreement continues to be used to manage migration flows between France and the UK. It enables the return of illegal migrants seeking to irregularly enter both the UK and France.

The agreement is invoked when an individual without leave in either the UK or France seeks to enter via the Eurotunnel or Channel Port, when we can clearly indicate the time of embarkation and the individual does not claim asylum at the port.

We continue to work with France on this global migration crisis. We are aiming for solutions to collectively address the wide range of factors associated with migrant movements across Europe and the Channel.

Since its launch, we have commenced the recruitment process for the Chair of the Mission. Once the Chair has been appointed, governance structures and terms of reference will be developed.

There is no intention to set out a specific spending plan.

Civil servants from the Office for Life Sciences, Department for Health and Social Care and Department for Business, Energy and Industrial Strategy have been developing the Mission and will continue to be represented in any new governance structures and in supporting the Chair, once recruited. The Senior Responsible Officer for the mission will also be a civil servant.

Disease control is a devolved matter, and it is for the devolved administrations to assess their disease risks and respond accordingly. However, each of the administrations seeks consistent and coordinated response to disease control across Great Britain (GB) where possible. Avian influenza control measures for the three GB administrations are set out in the GB notifiable avian disease control strategy (copy also attached to this answer).

As part of the coordinated GB response to avian influenza, the Animal and Plant Health Agency (APHA) carries out year-round avian influenza surveillance of dead wild birds submitted via public reports and warden patrols on behalf of Defra, the Scottish Government and the Welsh Government to help us understand how the disease is distributed geographically and in different types of bird. Through this surveillance, wild birds including Eider ducks, great black-backed gulls, gannets and Arctic terns have been found positive for highly pathogenic avian influenza (HPAI) H5N1 on Shetland. The Scottish Government is working closely with APHA, NatureScot and other non-governmental organisations including the Royal Society for the Protection of Birds and the British Trust for Ornithology to monitor and respond to the effect of avian influenza on wild birds on Shetland and other areas of Scotland.

There have been no specific discussions. However, the Department is preparing a new dementia strategy, which will include a focus on prevention and risk reduction. As part of this work, in December 2021 the Department had discussions with the British Academy of Audiology on hearing loss as a risk factor for dementia.

The Future of UK Clinical Research Delivery: 2021 to 2022 Implementation Plan sets out our commitments to improve study approval and set-up processes. This states that the Medicines and Healthcare products Regulatory Agency and the UK Research Ethics Services plan to implement a combined review of clinical trials to improve study approval. It aims to deliver a streamlined and efficient approval process through a single application route and a coordinated review. We also plan to introduce a National Contract Value Review to accelerate commercial research studies in the National Health Service. While the Implementation Plan is not specific to any disease area, it aims to benefit the research system, including trials for dementia. A copy of the Implementation Plan is attached.

We are reviewing ways to increase research for dementia and we will set out these ambitions in the forthcoming dementia strategy, which will be published later this year.

We will set out plans for dementia in England, which will include a focus on dementia diagnosis, later this year.

The National Institute for Health and Care Excellence’s (NICE) guidelines provide evidence-based recommendations for health and care, including on assessment, management and support for people living with dementia and their carers. NICE’s guideline Dementia: assessment, management and support for people living with dementia and their carers states that clinicians should consider FDG-PET and CSF tests when the diagnosis of Alzheimer’s disease is uncertain. A copy of the guideline is attached.

Clinical commissioning groups (CCGs) commission the appropriate resources, including such testing, in line with local population health needs. To address dementia waiting lists and increase the number of diagnoses, NHS England and NHS Improvement was allocated £17 million through the Comprehensive Spending Review settlement for mental health in 2021/22. This funding was made available to CCGs in June 2021.

We will set out our plans for dementia in England later this year. The strategy will focus on the specific health and care needs of people living with dementia and their carers, including dementia diagnosis, risk reduction and prevention and research. We will work with delivery partners to identify appropriate key performance indicators to monitor progress and assess the success of the strategy.

We will set out our plans for dementia in England later this year. The strategy will outline ambitions to increase dementia research and the delivery of the moonshot.

Regular communications are issued to members and staff to provide guidance in relation to Covid-19. The latest guidance, published on 5 April, states that from 25 April when the House returns from recess, the wearing of face masks is a matter of personal choice. All Covid-related measures are kept under review as appropriate.

The Government announced in November that the fourth Contracts for Difference allocation round will feature a £20 million annual ringfenced budget for tidal stream energy.

The Government remains open to considering well-developed proposals for harnessing the tidal range energy in the bays and estuaries around the UK’s coastlines, including barrage schemes and other alternatives. Any proposal would need to demonstrate strong evidence of value for money before the Government could take a view on its potential.

The Government will invest at least £375 million in neurodegenerative disease research over the next five years to fund projects into a range of diseases, including the causes of and treatments for dementia. The National Institute for Health Research and UK Research and Innovation rely on researchers submitting high-quality applications to access funding. Therefore, details of allocations and timescales are not currently available. All applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.

Thrombectomy is available in 24 centres in England. There are two non-neuroscience centres currently under development to improve access to thrombectomy.

The National Health Service is committed increasing the delivery of mechanical thrombectomy to 10% of cases. The latest data shows that 2.1% of patients are receiving a thrombectomy following a stroke. In early 2022, the NHS will undertake a quality review in England to resolve local barriers to increasing the uptake of thrombectomy.

The Government has committed to exploring proposals for introducing a landlord register in England as part of a commitment to bring forward reforms to drive improvements in privately rented accommodation and support local authorities to conduct well targeted effective enforcement that drives out criminal landlords.

We have conducted an initial phase of user research with a range of potential users of a register such as private landlords, local authority enforcement officers, letting agents and tenants. We will publish a White Paper in Spring this year that will set out our proposals for reform of the private rented sector.